Basiliximab
- Generic Name
- Basiliximab
- Brand Names
- Simulect
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 179045-86-4
- Unique Ingredient Identifier
- 9927MT646M
- Background
A recombinant chimeric (murine/human) monoclonal antibody (IgG1k) that functions as an immunosuppressive agent, specifically binding to and blocking the interleukin-2 receptor a-chain (IL-2R alpha, also known as CD25 antigen) on the surface of activated T-lymphocytes. It is a 144 kDa glycoprotein obtained from fermentation of an established mouse myeloma cel...
- Indication
For prophylactic treatment of kidney transplant rejection
- Associated Conditions
- Rejection Acute Renal
- Associated Therapies
- -
Effectiveness and Safety of a Single-Center Clinical Study on a CD25 Monoclonal Antibody-Containing GVHD Prophylaxis Scheme to Reduce the Incidence of Severe Acute GVHD After Umbilical Cord Blood Transplantation for Malignant Hematologic Diseases
- Conditions
- Interventions
- First Posted Date
- 2024-06-28
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Anhui Provincial Hospital
- Target Recruit Count
- 39
- Registration Number
- NCT06480630
- Locations
- 🇨🇳
The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei, China
1 Vs 7 RATG Infusions in Renal Transplantation
- First Posted Date
- 2024-04-18
- Last Posted Date
- 2024-11-28
- Target Recruit Count
- 75
- Registration Number
- NCT06374095
- Locations
- 🇮🇹
ASST HPG23 - Unità di Nefrologia, Bergamo, BG, Italy
Vedolizumab, Anti-CD25 Antibody, Rapid Reduction of Glucocorticoids for SR-aGVHD With Gastrointestinal Involvement
- First Posted Date
- 2023-10-04
- Last Posted Date
- 2023-10-04
- Target Recruit Count
- 45
- Registration Number
- NCT06066840
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Induction in Sensitized Kidney Transplant Recipients Without Pre-existing Donor-specific antiboDies
- Conditions
- Interventions
- First Posted Date
- 2022-05-23
- Last Posted Date
- 2023-09-05
- Lead Sponsor
- University Hospital, Tours
- Target Recruit Count
- 244
- Registration Number
- NCT05385432
Combination of Basiliximab and Pegaspargase in the Treatment of ENKTCL
- First Posted Date
- 2020-04-07
- Last Posted Date
- 2020-04-07
- Lead Sponsor
- Beijing Tongren Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT04337593
Impact of Lymphocyte Anti-metabolite Immunosuppressions on Donor-Specific Anti-HLA Antibody and Kidney Graft Outcome
- Conditions
- Interventions
- First Posted Date
- 2019-01-07
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 169
- Registration Number
- NCT03794492
- Locations
- 🇰🇷
Ajou University Hospital, Suwan, Korea, Republic of
Basiliximab Treating Interstitial Pneumonia of CADM
- Conditions
- Interventions
- First Posted Date
- 2017-06-20
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT03192657
- Locations
- 🇨🇳
RenJi Hospital, Shanghai, Shanghai, China
Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major
- First Posted Date
- 2017-05-31
- Last Posted Date
- 2017-05-31
- Target Recruit Count
- 30
- Registration Number
- NCT03171831
- Locations
- 🇨🇳
First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
Basiliximab vs Low-dose Thymoglobulin Induction Therapy in Low Risk Kidney Transplant Patients
- Conditions
- Interventions
- First Posted Date
- 2016-12-30
- Last Posted Date
- 2019-11-15
- Lead Sponsor
- Coordinación de Investigación en Salud, Mexico
- Target Recruit Count
- 100
- Registration Number
- NCT03006419
- Locations
- 🇲🇽
Umae Hospital Especialidades 14 Adolfo Ruiz Cortines, Veracruz, Mexico
Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients
- First Posted Date
- 2016-10-03
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 67
- Registration Number
- NCT02921789
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸Washington University in St. Louis, Saint Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.